for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TRACON Pharmaceuticals Inc

TCON.OQ

Latest Trade

3.20USD

Change

-0.05(-1.54%)

Volume

1,733

Today's Range

2.91

 - 

3.20

52 Week Range

2.80

 - 

17.30

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

TRACON Pharmaceuticals Inc Files For Offering Of Up To 1.64 Mln Shares - SEC Filing

Nov 12 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 1.64 MILLION SHARES OF COMMON STOCK - SEC FILING.

TRACON Pharmaceuticals Reports Third Quarter Results

Nov 5 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $19.1 MILLION AT SEPTEMBER 30, 2019.QTRLY LOSS PER SHARE $0.17.Q4 EARNINGS PER SHARE VIEW $-0.21 -- REFINITIV IBES DATA.

Tracon Pharmaceuticals Announces $15 Mln Common Stock Purchase Agreement With Aspire Capital Fund

Oct 21 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS ANNOUNCES $15 MILLION COMMON STOCK PURCHASE AGREEMENT WITH ASPIRE CAPITAL FUND, LLC.

Tracon Pharmaceuticals Says Qtrly Loss Per Share $0.21

Aug 7 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS - CASH, CASH EQUIVALENTS & SHORT-TERM INVESTMENTS WERE $26.3 MILLION AT JUNE 30, 2019, VERSUS $39.1 MILLION AT DECEMBER 31, 2018..QTRLY LOSS PER SHARE $0.21.Q2 EARNINGS PER SHARE VIEW $-0.19 -- REFINITIV IBES DATA.

Tracon Pharmaceuticals Provides Update On Phase 1/2 Trial Of Trc253

July 2 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1/2 TRIAL OF TRC253 IN PATIENTS WITH METASTATIC CASTRATE RESISTANT PROSTATE CANCER.TRACON PHARMACEUTICALS INC - PHASE 1 DATA PUBLISHED IN ASCO PROCEEDINGS DETERMINED RECOMMENDED PHASE 2 DOSE.TRACON PHARMACEUTICALS INC - ADDITIONAL COHORT OF PATIENTS WITH A SPECIFIC ANDROGEN RECEPTOR POINT MUTATION ADDED TO ONGOING PHASE 2 STUDY.TRACON PHARMACEUTICALS INC - PHASE 2 DATA EXPECTED IN 2(ND) HALF 2020; POTENTIAL FOR $45 MILLION OPT-IN PAYMENT FROM JANSSEN.TRACON PHARMACEUTICALS INC - TRC253 WAS WELL-TOLERATED AND NO DRUG-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED.

Tracon Pharmaceuticals Reports Qtrly Loss Per Share $0.24

May 14 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC - CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS WERE $32.1 MILLION AT MARCH 31, 2019, COMPARED TO $39.1 MILLION AT DECEMBER 31.TRACON PHARMACEUTICALS INC - EXPECT CURRENT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TO FUND OPERATIONS INTO Q3 OF 2020.TRACON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.24.TRACON PHARMACEUTICALS INC - COLLABORATION REVENUE WAS $0 FOR Q1 OF 2019 COMPARED TO $3.0 MILLION FOR Q1 OF 2018.

Tracon Pharmaceuticals Announces Termination Of Phase 3 Tappas Trial

April 12 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF PHASE 3 TAPPAS TRIAL BASED ON THE RECOMMENDATION OF THE INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - TRIAL WAS TERMINATED FOR FUTILITY BASED ON RECOMMENDATION OF INDEPENDENT DATA MONITORING COMMITTEE.TRACON PHARMACEUTICALS INC - WILL WORK WITH INVESTIGATORS TO APPROPRIATELY CONCLUDE STUDY.TRACON PHARMACEUTICALS INC - ANTICIPATE CURRENT CASH RUNWAY WILL NOW EXTEND INTO Q3 OF 2020.TRACON PHARMACEUTICALS INC - WILL TERMINATE FURTHER ENROLLMENT IN COMPANY SPONSORED TRIALS OF TRC105 IN ONCOLOGY..TRACON PHARMACEUTICALS INC - WILL CONTINUE TO SUPPORT PARTNER, SANTEN, IN THEIR DEVELOPMENT OF DE-122 IN WET AMD.TRACON PHARMACEUTICALS INC - WILL ALSO CONTINUE TO DEVELOP OTHER DRUG CANDIDATES, INCLUDING TRC253 IN PARTNERSHIP WITH JANSSEN.TRACON PHARMACEUTICALS INC - INTEND TO ADVANCE CANDIDATES WITHIN I-MAB'S BROAD BISPECIFIC PIPELINE INTO CLINIC IN US AS EARLY AS BEGINNING OF NEXT YEAR.

Tracon Pharmaceuticals Files For Mixed Shelf Of Upto $100 Mln

March 1 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.

Tracon Pharmaceuticals Reports Fourth Quarter Results

Feb 28 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.TRACON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.26.

TRACON Pharmaceuticals Presents Positive Top-Line Clinical Data From Dose Escalation Portion Of Phase 1 Trial Of TRC105 And Opdivo For Treatment Of Non-Small Cell Lung Cancer

Dec 26 (Reuters) - TRACON Pharmaceuticals Inc <TCON.O>::TRACON PHARMACEUTICALS PRESENTS POSITIVE TOP-LINE CLINICAL DATA FROM DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF TRC105 AND OPDIVO® FOR TREATMENT OF NON-SMALL CELL LUNG CANCER.TRACON - COMBINATION OF TRC105 & OPDIVO WELL-TOLERATED WITHOUT DEVELOPMENT OF DOSE LIMITING TOXICITY IN 6 PATIENTS TREATED AS PART OF DOSE ESCALATION.TRACON PHARMACEUTICALS INC - EXPECT TO PRESENT DATA FROM EXPANSION COHORTS IN MID-2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up